ArticleJournal of virology2023
Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner.
Article in Journal of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 14 citations in OpenAlex.
- A TRAC-478-adjuvanted recombinant N1 neuraminidase influenza virus vaccine induces balanced and broadly protective immune responses.NPJ vaccines · 2026Article
- Pre-Exposure Intranasal Treatment with Neomycin Sulfate Reduces Transmission of Influenza B Virus.Antibiotics (Basel, Switzerland) · 2026Article
- Anti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A/H3N2 virus.Nature communications · 2025Article
- Article
- The Persistence of Cross-Reactive Immunity to Influenza B/Yamagata Neuraminidase Despite the Disappearance of the Lineage: Structural and Serological Evidence.International journal of molecular sciences · 2025Article
- Preexisting immunity to the 2009 pandemic H1N1 virus reduces susceptibility to H5N1 infection and disease in ferrets.Science translational medicine · 2025Article
- Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants.NPJ vaccines · 2025Article
- Identification of a seasonal influenza vaccine-induced broadly protective neuraminidase antibody.The Journal of experimental medicine · 2025Article
- Article
- Aerosol immunization with influenza matrix, nucleoprotein, or both prevents lung disease in pig.NPJ vaccines · 2024Article
- CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice.NPJ vaccines · 2024Article
- Influenza B Virus Vaccine Innovation through Computational Design.Pathogens (Basel, Switzerland) · 2024Review
Corrections and comments
- Update of
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
importanceVaccines that can slow respiratory virus transmission in the population are urgently needed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus. Here, we describe how a recombinant neuraminidase-based influenza virus vaccine reduces transmission in vaccinated guinea pigs in an exposure intensity-based manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.